- Trial phase
- Approved
- Time to market
- Already approved and commercially available in both the US (since September 2024) and China (since June 2026).
- Why 4/10
- KarXT is already approved in both the US (by BMS) and China (by Zai Lab). No hard, dated binary catalyst (PDUFA, pivotal readout, AdComm) remains for this drug in the next ~12 months for Zai Lab. The defining binary events have passed; the focus is on commercial ramp and NRDL negotiation, which are gradual, not binary. ImpactScore defaults to 4 for an approved, commercial-stage drug with no pending regulatory decision.
KarXT is already approved and launching in China, so the next stock-moving events for Zai Lab around this drug are commercial milestones: NRDL (national reimbursement) negotiation outcomes, quarterly sales growth trends, and any label expansion for Alzheimer's psychosis or bipolar mania that Zai Lab might pursue in China. The next major binary catalyst for Zai Lab overall is the November 30, 2026 PDUFA date for povetacicept in IgAN, not KarXT.
Price Chart
Executive Summary
KarXT (xanomeline/trospium chloride), sold as Cobenfy in the US and as Karigel/Kaigele in China, is a first-in-class oral medication for schizophrenia that works through muscarinic receptors rather than the traditional dopamine-blocking pathway. Developed by Karuna Therapeutics (acquired by Bristol-Myers Squibb for $14 billion), it was FDA-approved in the US in September 2024. Zai Lab (ZLAB) holds exclusive rights for Greater China under a 2021 licensing deal. China's NMPA approved KarXT in December 2025, and Zai Lab commercially launched it in mainland China in June 2026. For Zai Lab investors, the defining binary catalysts (US FDA approval, China NMPA approval) have already passed; the focus now is on commercial execution, NRDL reimbursement negotiation, and revenue contribution alongside Zai Lab's broader pipeline.
How It Works
KarXT is a combination of two drugs in one pill. Xanomeline activates muscarinic receptors (M1/M4) in the brain to improve schizophrenia symptoms, while trospium chloride blocks those same receptors in the rest of the body to reduce side effects like nausea and vomiting. This is the first schizophrenia drug in decades that works through this muscarinic pathway instead of blocking dopamine receptors.
Trial Status
FDA approved in the US (September 2024) and NMPA approved in China (December 2025). Commercially launched in mainland China in June 2026. Phase 3 trials for bipolar mania (BALSAM-2) and Alzheimer's disease psychosis (ADEPT program) are ongoing globally, led by Bristol-Myers Squibb. Zai Lab is conducting a real-world study in Chinese schizophrenia patients.
The Two-Sided Case
Upcoming Catalysts
- NRDL (National Reimbursement Drug List) negotiation outcome for KarXT in China - timing uncertain but typically annual cycle.
- Quarterly sales growth trajectory for KarXT in China (next earnings likely early 2027 for Q4 2026).
- BMS-led Phase 3 readouts for KarXT in bipolar mania and Alzheimer's psychosis - these are global trials, not Zai Lab-specific, but positive data could support future China label expansion.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zai Lab Ltd 8-K ZLAB ·Originating report